Concentration control: a key to phase I development of immunosuppressive agents.
Kahan
B D
BD
Department of Surgery, University of Texas Medical School, Houston 77030.
D017321:Clinical Trials, Phase I as Topic / Q000379:methods*; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D016572:Cyclosporine / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000493:pharmacokinetics / Q000627:therapeutic use / Q000633:toxicity*; D016030:Kidney Transplantation / Q000276:immunology; D011090:Polyenes / Q000493:pharmacokinetics / Q000627:therapeutic use / Q000633:toxicity*; D006435:Renal Dialysis; D012107:Research Design; D020123:Sirolimus
D007166:Immunosuppressive Agents; D011090:Polyenes; D016572:Cyclosporine; D020123:Sirolimus